NASDAQ:EPIX ESSA Pharma Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ESSA Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.45 -0.48 (-6.93 %) (As of 09/23/2020 12:00 AM ET) Add Compare Share Today's Range$6.09Now: $6.45▼$6.9950-Day Range$6.70MA: $7.07▼$7.7952-Week Range$2.85Now: $6.45▼$8.31Volume119,351 shsAverage Volume62,588 shsMarket Capitalization$193.69 millionP/E RatioN/ADividend YieldN/ABeta1.7 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media ESSA Pharma Inc., a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingESSA Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, ESSA Pharma has a forecasted upside of 39.5% from its current price of $6.45.Amount of Analyst CoverageESSA Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesESSA Pharma has received 330 “outperform” votes. (Add your “outperform” vote.)Underperform VotesESSA Pharma has received 212 “underperform” votes. (Add your “underperform” vote.)Community SentimentESSA Pharma has received 60.89% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ESSA Pharma and other stocks. Vote “Outperform” if you believe EPIX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EPIX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldESSA Pharma does not currently pay a dividend.Dividend GrowthESSA Pharma does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ESSA Pharma insiders have not sold or bought any company stock.Percentage Held by Institutions48.49% of the stock of ESSA Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ESSA Pharma are expected to grow in the coming year, from ($1.14) to ($0.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ESSA Pharma is -7.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ESSA Pharma is -7.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioESSA Pharma has a P/B Ratio of 2.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.63 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EPIX Previous Symbol CUSIPN/A CIK1633932 Webwww.essapharma.com Phone778-331-0962Debt Debt-to-Equity RatioN/A Current Ratio29.77 Quick Ratio29.77Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.37 per share Price / Book2.72Profitability EPS (Most Recent Fiscal Year)($1.46) Net Income$-10,440,000.00 Net MarginsN/A Return on Equity-45.83% Return on Assets-43.36%Miscellaneous Employees15 Outstanding Shares30,029,000Market Cap$193.69 million Next Earnings Date12/17/2020 (Estimated) OptionableNot Optionable $6.45 -0.48 (-6.93 %) (As of 09/23/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive EPIX News and Ratings via Email Sign-up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter. ESSA Pharma (NASDAQ:EPIX) Frequently Asked Questions How has ESSA Pharma's stock price been impacted by Coronavirus? ESSA Pharma's stock was trading at $4.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EPIX stock has increased by 58.5% and is now trading at $6.45. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of ESSA Pharma? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ESSA Pharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ESSA Pharma. When is ESSA Pharma's next earnings date? ESSA Pharma is scheduled to release its next quarterly earnings announcement on Thursday, December 17th 2020. View our earnings forecast for ESSA Pharma. How were ESSA Pharma's earnings last quarter? ESSA Pharma Inc (NASDAQ:EPIX) posted its quarterly earnings results on Thursday, August, 6th. The company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.05. View ESSA Pharma's earnings history. What price target have analysts set for EPIX? 3 Wall Street analysts have issued 1 year price targets for ESSA Pharma's shares. Their forecasts range from $9.00 to $9.00. On average, they anticipate ESSA Pharma's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 39.5% from the stock's current price. View analysts' price targets for ESSA Pharma. Are investors shorting ESSA Pharma? ESSA Pharma saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 24,300 shares, a decrease of 20.8% from the August 15th total of 30,700 shares. Based on an average daily volume of 110,900 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.2% of the shares of the company are short sold. View ESSA Pharma's Short Interest. Who are some of ESSA Pharma's key competitors? Some companies that are related to ESSA Pharma include Morphic (MORF), Protagonist Therapeutics (PTGX), Phibro Animal Health (PAHC), Endo International (ENDP), RAPT Therapeutics (RAPT), VBI Vaccines (VBIV), Provention Bio (PRVB), Frequency Therapeutics (FREQ), Emisphere Technologies (EMIS), DiaMedica Therapeutics (DMCAF), Kadmon (KDMN), Spectrum Pharmaceuticals (SPPI), Cara Therapeutics (CARA), ImmunoGen (IMGN) and Northwest Biotherapeutics (NWBO). View all competitors. What other stocks do shareholders of ESSA Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include REDHILL BIOPHAR/S (RDHL), Aurinia Pharmaceuticals (AUPH), Lipocine (LPCN), Trevena (TRVN), Allena Pharmaceuticals (ALNA), Protalix Biotherapeutics (PLX), Agile Therapeutics (AGRX), Biopharmx (BPMX), Corbus Pharmaceuticals (CRBP) and Heat Biologics (HTBX). Who are ESSA Pharma's key executives? ESSA Pharma's management team includes the following people: Dr. David Ross Parkinson, Pres, CEO & Director (Age 69)Mr. David S. Wood, Chief Financial Officer (Age 62)Mr. Peter A. Virsik, Exec. VP & COO (Age 48)Dr. Raymond Andersen, CTO, Sec. & Director (Age 72)Dr. Marianne D. Sadar, Chief Scientific Officer & Director (Age 58) What is ESSA Pharma's stock symbol? ESSA Pharma trades on the NASDAQ under the ticker symbol "EPIX." Who are ESSA Pharma's major shareholders? ESSA Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include BVF Inc. IL (9.52%), Omega Fund Management LLC (7.18%), Opaleye Management Inc. (0.84%) and Commonwealth Equity Services LLC (0.12%). Which major investors are selling ESSA Pharma stock? EPIX stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, and Omega Fund Management LLC. Which major investors are buying ESSA Pharma stock? EPIX stock was acquired by a variety of institutional investors in the last quarter, including Opaleye Management Inc., and Commonwealth Equity Services LLC. How do I buy shares of ESSA Pharma? Shares of EPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is ESSA Pharma's stock price today? One share of EPIX stock can currently be purchased for approximately $6.45. How big of a company is ESSA Pharma? ESSA Pharma has a market capitalization of $193.69 million. The company earns $-10,440,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis. ESSA Pharma employs 15 workers across the globe. What is ESSA Pharma's official website? The official website for ESSA Pharma is www.essapharma.com. How can I contact ESSA Pharma? ESSA Pharma's mailing address is 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5. The company can be reached via phone at 778-331-0962 or via email at [email protected] This page was last updated on 9/23/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
